Plasma transforming growth factor-β1 concentrations in patients with chronic viral hepatitis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 13, Issue 7, 1998, Pages 680-684

  Murawaki, Yoshikazu ^a   Nishimura, Yuuko ^a   Ikuta, Yujiro ^a   Idobe, Youko ^a   Kitamura, Yukisato ^a   Kawasaki, Hironaka ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Chronic viral hepatitis; Hepatic fibrosis; Transforming growth factor 1

Indexed keywords

COLLAGEN TYPE 4; CYTOKINE; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; MALE; PRIORITY JOURNAL; VIRUS HEPATITIS;

EID: 0031785045     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.1998.tb00713.x     Document Type: Article

References (28)

1. Gressner AM. Mediators of hepatic fibrogenesis. Hepatogastroenterology 1996; 43: 92-103.
2. Roberts AB, McCune BK, Sporn MB.TGF-β: Regulation of extracellular matrix. Kidney International 1992; 41: 557-9.
3. Border WA, Noble NA. Transforming growth factor βin tissue fibrosis. N. Engl. J. Med. 1994; 331: 1286-92.
4. Bedossa P, Paradis V Transforming growth factor-β (TGF-β): A key role in liver fibrogenesis. J. Hepatol. 1995; 22 (Suppl. 2): 37-42.
5. Castilla A, Prieto J, Fausto N. Transforming growth factors β1 and α in chronic liver disease: Effects of interferon alfa therapy. N. Engl. J. Med. 1991; 324: 933-40.
6. Nagy P, Schaff Z, Lapis K. Immunohistochemical detection of transforming growth factor-β1 in fibrotic liver diseases. Hepatology 1991; 14: 269-73.
7. Annoni G, Weiner FR, Zern MA. Increased transforming growth factor-β1 gene expression in human liver disease. J. Hepatol. 1992; 14: 259-64.
8. Napoli J, Bishop GA, McCaughan GW. Increased intrahepatic messenger RAN expression of interleukins 2, 6 and 8 in human cirrhosis. Gastroenterology 1994; 107: 789-98.
9. Roulot D, Durand H, Coste T et al. Quantitative analysis of transforming growth factor β1 messenger RNA in the liver of patients with chronic hepatitis C: Absence of correlation between high levels and severity of disease. Hepatology 1995; 21: 298-304.
10. Bedossa P, Peltier E, Terris B, Franco D, Poynard T. Transforming growth factor-beta 1 (TGF-β1) and TGF-β1 receptors in normal, cirrhotic and neoplastic human livers. Hepatology 1995; 21: 760-6.
11. Czaja MJ, Weiner FR, Flanders KC et al. In vitro and in vivo association of transforming growth factor-β1 with hepatic fibrosis. J. Cell Biol. 1989; 108: 2477-82.
12. Nakastukasa H, Nagy P, Evarts RP, Hsia C-C, Marsden E, Thorgeirsson SS. Cellular distribution of transforming growth factor-β1 and procollagen types I, III and IV transcripts in carbon tetrachloride-induced rat liver fibrosis. J. Clin. Invest. 1990; 85: 1833-43.
13. Kresma TF, He Q, Esposti SD, Zern MA. Gene expression of transforming growth factor β1 and extracellular matrix proteins in murine schistosoma mansoni infection. Gastroenterology 1994; 107: 773-80.
14. Massague J. The transforming growth factor-β family. Ann. Rev. Cell Biol. 1990; 6: 597-641.
15. Murawaki Y, Ikuta Y, Nishimura Y, Koda M, Kawasaki H. Serum markers for fibrosis and plasma transforming growth factor-β1 in patients with hepatocellular carcinoma in comparison with patients with liver cirrhosis. J. Gastroenterol. Hepatol. 1996; 11: 443-50.
16. Shirai Y, Kawata S, Tamura S et al. Plasma transforming growth factor-β1 in patients with hepatocellular carcinoma. Cancer 1994; 73: 2275-9.
17. Knodell RG, Ishak KG, Black WC et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5.
18. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513-20.
19. Shahin M, Schuppan D, Waldherr R et al. Serum procollagen peptides and collagen type VI for the assessment of activity and degree of hepatic fibrosis in schistosomiasis and alcoholic liver disease. Hepatology 1992; 15: 637-44.
20. Murawaki Y, Ikuta Y, Koda M, Yamada S, Kawasaki H. Comparison of serum 7S fragment of type IV collagen and serum central triple-helix of type IV collagen for assessment of liver fibrosis in patients with chronic viral liver disease. J. Hepatol. 1996; 24: 148-54.
21. Obata K, Iwata K, Ichida T et al. One step sandwich enzyme immunoassay for human type IV collagen using monoclonal antibodies. Clin. Chim. Acta 1989; 181: 293-304.
22. Casini A, Pinzani M, Milani S et al. Regulation of extracellular matrix synthesis by transforming growth factor β1 in human fat-storing cells. Gastroenterology 1993; 105: 245-53.
23. Murawaki Y, Ikuta Y, Koda M, Kawasaki H. Serum type-III procollagen peptide, type IV collagen 7S domain, central triple-helix of type IV collagen and tissue inhibitor of metalloproteinases in patients with chronic viral liver disease: Relationship to liver histology. Hepatology 1994; 20: 780-7.
24. Kaname S, Ruoslahti E. Betaglycan has multiple binding sites for transforming growth factor β1. Biochem. J. 1996; 315: 815-20.
25. Feige J-J, Negoescu A, Keramidas M, Souchelnitskiy S, Chambaz EM. α2-Macroglobulin: A binding protein for transforming growth factor-β and various cytokines. Horm. Res. 1996; 45: 227-32.
26. Coffey RJ, Kost LJ, Lyons RM, Moses HL, LaRusso NF. Hepatic processing of transforming growth factor β in the rat: Uptake, metabolism and biliary excretion. J. Clin. Invest. 1987; 80: 750-7.
27. Wakefield LM, Winokur TS, Hollands RS, Christopherson K, Levinson AD, Sporn MB. Recombinant latent transforming growth factor β1, and a different tissue distribution. J. Clin. Invest. 1990; 86: 1976-84.
28. O'Connor-McCour MD, Wakefield LM. Latent transforming growth factor-β in serum: A specific complex with α2-macroglobulin. J. Biol. Chem. 1987; 262: 14 090-9.